Reports Q4 revenue $657.29M, consensus $646.19M. “I’m proud of our team at Globus Medical (GMED), delivering incredible results for 2024. We made significant progress integrating the business and creating a strong foundation for future growth while remaining focused on improving patient outcomes. Our spine sales force is the most dedicated and talented team in the market. Our innovation engine delivered a record amount of new product launches in 2024 and remains unmatched in our industry.” said Dan Scavilla, President and CEO. “The potential for Globus has never been greater, as we continue to redefine spine surgery and address unmet clinical needs with procedural solutions built around enabling technology.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- GMED Earnings this Week: How Will it Perform?
- Strategic Acquisition of NVRO Boosts Globus Medical’s Market Position and Growth Prospects
- Nevro price target raised to $5.85 from $5 at Baird
- Strategic Acquisition of Nevro Positions Globus Medical for Long-Term Growth and Market Leadership
- Nevro price target raised to $5.85 from $4 at Canaccord